Wegovy® pill showed a mean weight loss of 16.6% in the OASIS 4 trial[1]
Wegovy® pill is indicated to reduce excess body weight and maintain weight reduction long-term and to reduce the risk of major adverse cardiovascular events*
Novo Nordisk expects to launch Wegovy® pill in the US in early January 2026
Dubai, 24 December 2025- Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved the Wegovy® pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events*.
Deputy Director General Susan Chi Chuan Hu of TITA and Executive VP Joe Chou of TAITRA, together with the judging panel, joined the winning teams for a group photo.
Not so long ago, undergoing a total hip or knee replacement and recovery was a grueling and often painful ordeal. While these are still major surgeries, new techniques and technologies are redefining them — and improving people’s outcomes, explains Dr. Brandon Bukowski, an orthopedic surgeon at the Mayo Clinic Health System in Mankato.
The newly licensed intrathecal gene therapy, enhances life-changing treatment options for children and families affected by Spinal Muscular Atrophy
Dubai, UAE–22December 2025: Families who were previously informed that their children had outgrown the eligibility for SMA gene therapy or were deemed not the right weight, now have renewed hope. Medcare Royal Speciality Hospital in Al Qusais has become among the first centres outside the USA to offer a newly licensed intrathecal gene therapy for Spinal Muscular Atrophy (SMA).
This treatment can now be administered to SMA patients well into their childhood and beyond. Approved after a thorough global assessment for intrathecal use, this therapy is tailored for children, teenagers, and adults, effectively removing the weight restrictions that have historically hindered access to gene therapy for this rare neuromuscular disorder.The milestone solidifies the UAE’s position at the forefront of cutting-edge genetic medicine and brings new hope to thousands of families worldwide.
A new three-drug immunotherapy combination significantly improves outcomes for relapsed follicular lymphoma, offering a chemotherapy-free treatment option
DUBAI, RIYADH, DOHA,DECEMBER 22nd, 2025.Memorial Sloan Kettering Cancer Center (MSK), one of the world’s leading cancer treatment, education and research institutions, has released clinical trial resultsshowing that a new three-drug immunotherapy combination provides significantly better outcomes for people with relapsed follicular lymphoma.
Follicular lymphoma is a slow-growing form of non-Hodgkin lymphoma that can become more aggressive over time. Treatment often works well at first, but many people experience relapse, and options become more limited with each recurrence. The development is particularly relevant for the Middle East, where hematologic cancers such as lymphoma and leukemia rank among the most common cancers in several countries, including the UAE, Saudi Arabia, and Kuwait, and where many patients face repeated relapses and limited treatment options.
The international phase 3 trial findings were announced at the American Society of Hematology (ASH) Annual Meeting. The trialfound that adding the bispecific antibody epcoritamab (Epkinly®) to rituximab (Rituxan®) and lenalidomide (Revlimid®) produced far stronger results than the standard two-drug regimen. The three-drug combination reduced the risk of cancer progression or death by nearly 80%; more than 95% of patients saw their cancer shrink (vs. 79%), and 82% had no detectable disease (vs. 50%). After 16 months, 85% remained progression-free, compared with 40% on standard treatment.
UAE News 24/7 